ERBB2 and metastatic colorectal cancer: The US Food and Drug Administration-approved anti-HER2 tucatinib plus trastuzumab treatment for chemotherapy-refractory ERBB2 (HER2)-positive RAS-wild type metastatic colorectal cancer has shown favorable outcomes [32].